首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Drug incorporation and release of water soluble drugs from novel functionalised poly(glycerol adipate) nanoparticles
【24h】

Drug incorporation and release of water soluble drugs from novel functionalised poly(glycerol adipate) nanoparticles

机译:新型功能化聚己二酸甘油酯纳米颗粒的药物掺入和水溶性药物的释放

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

We have previously demonstrated the ability of poly(glycerol adipate) backbone (PGA) and PGA polymer backbone substituted with varying amounts of pendant C-18 chain length acyl groups to yield Dexamethasone phosphate DXMP loaded nanoparticles. The aim of this study was to obtain a deeper understanding of the underlying principles responsible for good drug incorporation and controlled release of drugs from poly (glycerol adipate) (PGA) nanoparticles. We compared the incorporation of the water soluble drugs DXMP and Cytosine arabinoside (CYT-ARA) in both unmodified and substituted PGA polymers. We investigated the effect of change in acyl group chain length and the degree of substitution on the physicochemical properties, drug loading and release of DXMP and CYT-ARA. Nanoparticles were prepared by the interfacial deposition technique and the simultaneous emulsification method. Amongst the nanoparticles prepared using acylated polymers with varying chain lengths (C-2 to C-10) for DXMP incorporation, polymers with acyl group chain lengths containing 8 carbon atoms (C-8) showed maximum drug incorporation. Amongst the C-8 series, polymers with 100% acylation provided both good drug incorporation and a controlled release for DXMP while for CYT-ARA it was the unsubstituted polymer backbone that had maximum drug loading and slower release. A number of inter-related factors are responsible for producing particles with particular size, zeta potential, drug loading and release characteristics. Drug loading and release from nanoparticles are primarily influenced by the nature of interactions between the drug and polymers which in turn depend upon the type of drug used and the physical chemistry of the polymer. (C) 2007 Elsevier B.V. All rights reserved.
机译:我们之前已经证明了用变化量的C-18链长侧基酰基取代的聚己二酸甘油酯主链(PGA)和PGA聚合物主链能够产生磷酸地塞米松DXMP负载纳米颗粒。这项研究的目的是更深入地了解负责从聚己二酸甘油酯(PGA)纳米颗粒中良好掺入药物和控制释放药物的基本原理。我们比较了水溶性药物DXMP和胞嘧啶阿拉伯糖苷(CYT-ARA)在未修饰和取代的PGA聚合物中的掺入情况。我们调查了酰基链长度的变化和取代度对DXMP和CYT-ARA的理化性质,载药量和释放的影响。通过界面沉积技术和同时乳化法制备纳米颗粒。在使用具有变化的链长(C-2至C-10)的酰化聚合物用于DXMP掺入制备的纳米颗粒中,具有含8个碳原子的酰基链长的聚合物(C-8)显示出最大的药物掺入。在C-8系列中,具有100%酰化作用的聚合物既可为DXMP提供良好的药物掺入,又可提供受控释放,而对于CYT-ARA,未取代的聚合物主链具有最大的药物载量和较慢的释放。许多相互关联的因素导致产生具有特定大小,ζ电势,药物装载和释放特征的颗粒。药物从纳米颗粒的负载和释放主要受药物与聚合物之间相互作用的性质的影响,而相互作用的性质又取决于所用药物的类型和聚合物的物理化学。 (C)2007 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号